Unknown

Dataset Information

0

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma.

ABSTRACT: Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we identified two genes (ANLN and ARNTL2) from multiple gene expression data sets, and developed a two-mRNA-based signature that can effectively distinguish high- and low-risk patients and predict patients' response to immunotherapy. Furthermore, taking full advantage of the complementary value of clinical and molecular features, we combined the immune prognostic signature with clinical features to construct and validate a nomogram that can predict the probability of high tumor mutational burden (>10 mutations per megabyte). This may improve the estimation of immunotherapy response in LUAD patients, and provide a new perspective for clinical screening of immunotherapy beneficiaries.

SUBMITTER: Song C 

PROVIDER: S-EPMC7875126 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma.

Song Congkuan C   Wu Zhiquan Z   Wang Qingwen Q   Wang Yujin Y   Guo Zixin Z   Li Sheng S   Hu Weidong W  

Frontiers in cell and developmental biology 20210126

Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we identified two genes (ANLN and ARNTL2) from multiple gene expression data sets, and developed a two-mRNA-based signature that can effectively distinguish high- and low-risk patients and predict patients  ...[more]

Similar Datasets

Unknown Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.
| S-EPMC7934870 | biostudies-literature
Unknown Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
| S-EPMC7366360 | biostudies-literature
Unknown PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
| S-EPMC6225900 | biostudies-other
Unknown Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
| S-EPMC7744325 | biostudies-literature
Unknown Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
| S-EPMC5944039 | biostudies-literature
Unknown PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
| S-EPMC6482991 | biostudies-literature
Unknown MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
| S-EPMC7262882 | biostudies-literature
Unknown Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.
| S-EPMC7670562 | biostudies-literature
Unknown Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
| S-EPMC8484748 | biostudies-literature
Unknown Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
| S-EPMC6625041 | biostudies-literature